CN1138543C - 水不溶性喜树碱的类脂配合物的冷冻干燥制剂 - Google Patents
水不溶性喜树碱的类脂配合物的冷冻干燥制剂 Download PDFInfo
- Publication number
- CN1138543C CN1138543C CNB951956590A CN95195659A CN1138543C CN 1138543 C CN1138543 C CN 1138543C CN B951956590 A CNB951956590 A CN B951956590A CN 95195659 A CN95195659 A CN 95195659A CN 1138543 C CN1138543 C CN 1138543C
- Authority
- CN
- China
- Prior art keywords
- compositions
- camptothecine
- phospholipid
- freeze
- quasi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
实施例号 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
9-AC | 0.4mg | 0.4mg | 0.4mg | 0.4mg | 0.4mg | 0.4mg | 0.2mg | 0.2mg |
DMSO | 0.01ml | 0.01ml | 0.01ml | 8.7ml | 8.7ml | 10ml | 5ml | 5ml |
DMPC | 26mg | 24.2mg | 3.0mg | 22.4mg | 22.4mg | 22.4mg | 11.2mg | 8mg |
DMPG | 11.3mg | 10.4mg | 1.25mg | 9.6mg | 9.6mg | 9.6mg | 4.8mg | 8mg |
氯仿 | 0.25ml | 0.25ml | 0.31ml | 0.2ml | 0.2ml | 0.2ml | 0.1mg | 0.1ml |
甘露糖醇 | 15.1mg | 14.55mg | 14mg | 15mg | 15mg | 20mg | 20mg | 20mg |
枸椽酸钠 | 8.9mg | 9.9mg | ||||||
枸椽酸 | 14.7mg | 14.7mg | ||||||
WFI | ||||||||
冷动干燥制剂 | 0.4mg/瓶 | 0.4mg/瓶 | 0.4mg/瓶 | 0.2mg/瓶 | 0.2mg/瓶 | 2mg/瓶 | 1mg/瓶 |
4℃ | 27℃ | 37℃ | |
1周 | 99.3 | 97.7 | 99.7 |
2周 | 100.3 | 103.3 | 104.3 |
1月 | 103.7 | 97.7 | 102.3 |
2月 | 101 | 102.3 | 102.3 |
5月 | 106.4 | 105.7 | 104.7 |
7月 | 106.4 | 104.2 | --- |
CDF | |||
方案 | mg/kg剂量 | TTTD | 死亡数 |
I.V.小球Q4Dx6(6剂量 ) | 0 | 26.8 | 0 |
1.8 | 34.2 | 0 | |
2.7 | 38.9 | 2a | |
4.0 | 25.3 | 6a | |
I.V.小球Qdx412,19,26天(12剂量) | 0 | 26.3 | 0 |
0.9 | 35.4 | 0 | |
1.33 | 46.4c | 2b | |
2.0 | 50.9 | 7b | |
P.O.Q2Dx14 | 0 | 27.0 | 0 |
0.67 | 35.6 | 0 | |
1.0 | 33.7 | 0 | |
1.5 | 42.8 | 0 |
Claims (15)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32308194A | 1994-10-14 | 1994-10-14 | |
US08/323,081 | 1994-10-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1160344A CN1160344A (zh) | 1997-09-24 |
CN1138543C true CN1138543C (zh) | 2004-02-18 |
Family
ID=23257667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB951956590A Expired - Fee Related CN1138543C (zh) | 1994-10-14 | 1995-10-11 | 水不溶性喜树碱的类脂配合物的冷冻干燥制剂 |
Country Status (18)
Country | Link |
---|---|
US (1) | US6548071B1 (zh) |
EP (1) | EP0785772A4 (zh) |
JP (2) | JPH10507454A (zh) |
KR (1) | KR100387744B1 (zh) |
CN (1) | CN1138543C (zh) |
AU (1) | AU689983B2 (zh) |
CA (1) | CA2202531C (zh) |
HU (1) | HUT77975A (zh) |
IL (1) | IL115099A (zh) |
MY (1) | MY113203A (zh) |
NO (1) | NO323582B1 (zh) |
NZ (1) | NZ296389A (zh) |
PL (1) | PL183040B1 (zh) |
RU (1) | RU2169555C2 (zh) |
TW (1) | TW450811B (zh) |
UA (1) | UA64692C2 (zh) |
WO (1) | WO1996011669A1 (zh) |
ZA (1) | ZA957860B (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19758157A1 (de) | 1997-03-27 | 1998-10-01 | Sueddeutsche Kalkstickstoff | Homogene, Glycerophospholipide und polare oder lipophile Substanzen enthaltende, wasserfreie Formulierungen und Verfahren zu deren Herstellung |
GB9925127D0 (en) * | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
DE10234784A1 (de) * | 2002-07-30 | 2004-02-19 | Günenthal GmbH | Intravenös applizierbare, pharmazeutische Darreichungsform |
US7838034B2 (en) | 2002-07-30 | 2010-11-23 | Grunenthal Gmbh | Intravenous pharmaceutical form of administration |
US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
WO2004035032A2 (en) * | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
WO2005002546A1 (en) * | 2003-06-27 | 2005-01-13 | Smithkline Beecham Corporation | Stabilized topotecan liposomal composition and methods |
JP4433918B2 (ja) * | 2004-07-15 | 2010-03-17 | コニカミノルタエムジー株式会社 | 画像形成方法 |
KR100651728B1 (ko) * | 2004-11-10 | 2006-12-06 | 한국전자통신연구원 | 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법 |
CN1326525C (zh) * | 2004-11-26 | 2007-07-18 | 复旦大学 | 10-羟基喜树碱长循环脂质体及其冻干制剂 |
TW200727900A (en) * | 2005-07-27 | 2007-08-01 | Yakult Honsha Kk | Aqueous solution preparation containing camptothecins |
WO2007067784A2 (en) * | 2005-12-08 | 2007-06-14 | Wyeth | Liposomal compositions |
CN101028251B (zh) * | 2007-02-14 | 2010-05-19 | 四川大学 | 喜树碱衍生物磷脂复合物脂质纳米粒制剂及其制备方法 |
CN101721364B (zh) * | 2009-11-10 | 2014-05-21 | 沈阳药科大学 | 一种喜树碱类化合物磷脂复合物水分散体及其制备方法 |
KR102310697B1 (ko) | 2012-11-20 | 2021-10-12 | 스펙트럼 파마슈티컬즈 인크 | 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법 |
TWI678213B (zh) | 2015-07-22 | 2019-12-01 | 美商史倍壯製藥公司 | 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物 |
DE102018200520A1 (de) * | 2018-01-15 | 2019-07-18 | Robert Bosch Gmbh | Verfahren zum Bereitstellen einer Lösung der Substanz in einer mikrofluidischen Vorrichtung |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS180644B2 (en) * | 1973-09-29 | 1978-01-31 | Takeda Chemical Industries Ltd | Process for preparing nonapeptides |
GB1575343A (en) * | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
CH621479A5 (zh) * | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
US4610868A (en) | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US5279811A (en) * | 1987-02-18 | 1994-01-18 | The Du Pont Merck Pharmaceutical Company | Ester-substituted diaminedithiols and radiolabeled complexes thereof |
US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
MX9203504A (es) * | 1988-04-20 | 1992-07-01 | Liposome Co Inc | Complejo agente: lipido activo de alta proporcion. |
US5077057A (en) | 1989-04-05 | 1991-12-31 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US5389377A (en) | 1989-12-22 | 1995-02-14 | Molecular Bioquest, Inc. | Solid care therapeutic compositions and methods for making same |
US5552156A (en) * | 1992-10-23 | 1996-09-03 | Ohio State University | Liposomal and micellular stabilization of camptothecin drugs |
AU6832794A (en) * | 1993-05-19 | 1994-12-12 | Liposome Company, Inc., The | Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer |
JPH09504517A (ja) * | 1993-09-27 | 1997-05-06 | スミスクライン・ビーチャム・コーポレイション | カンプトテシン処方物 |
US5834012A (en) * | 1995-05-03 | 1998-11-10 | Roman Perez-Soler | Lipid complexed topoisomerase I inhibitors |
US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
-
1995
- 1995-08-29 IL IL11509995A patent/IL115099A/xx not_active IP Right Cessation
- 1995-09-18 TW TW084109751A patent/TW450811B/zh not_active IP Right Cessation
- 1995-09-18 ZA ZA957860A patent/ZA957860B/xx unknown
- 1995-10-11 NZ NZ296389A patent/NZ296389A/xx unknown
- 1995-10-11 AU AU40185/95A patent/AU689983B2/en not_active Ceased
- 1995-10-11 JP JP8513489A patent/JPH10507454A/ja active Pending
- 1995-10-11 KR KR1019970702418A patent/KR100387744B1/ko not_active IP Right Cessation
- 1995-10-11 WO PCT/US1995/014105 patent/WO1996011669A1/en active IP Right Grant
- 1995-10-11 PL PL95319588A patent/PL183040B1/pl not_active IP Right Cessation
- 1995-10-11 RU RU97107856/14A patent/RU2169555C2/ru not_active IP Right Cessation
- 1995-10-11 EP EP95939009A patent/EP0785772A4/en not_active Withdrawn
- 1995-10-11 CA CA002202531A patent/CA2202531C/en not_active Expired - Fee Related
- 1995-10-11 HU HU9800995A patent/HUT77975A/hu unknown
- 1995-10-11 CN CNB951956590A patent/CN1138543C/zh not_active Expired - Fee Related
- 1995-10-12 MY MYPI95003048A patent/MY113203A/en unknown
- 1995-11-10 UA UA97041743A patent/UA64692C2/uk unknown
-
1997
- 1997-04-11 NO NO19971668A patent/NO323582B1/no unknown
- 1997-06-10 US US08/871,558 patent/US6548071B1/en not_active Expired - Fee Related
-
2007
- 2007-09-19 JP JP2007242506A patent/JP2008024717A/ja not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL115099A (en) | 1999-04-11 |
EP0785772A1 (en) | 1997-07-30 |
ZA957860B (en) | 1996-05-21 |
JPH10507454A (ja) | 1998-07-21 |
JP2008024717A (ja) | 2008-02-07 |
US6548071B1 (en) | 2003-04-15 |
NO971668D0 (no) | 1997-04-11 |
NO971668L (no) | 1997-04-11 |
AU4018595A (en) | 1996-05-06 |
KR100387744B1 (ko) | 2003-11-28 |
KR970706792A (ko) | 1997-12-01 |
EP0785772A4 (en) | 2005-12-21 |
WO1996011669A1 (en) | 1996-04-25 |
AU689983B2 (en) | 1998-04-09 |
MY113203A (en) | 2001-12-31 |
CA2202531C (en) | 2005-05-03 |
CA2202531A1 (en) | 1996-04-25 |
PL319588A1 (en) | 1997-08-18 |
HUT77975A (hu) | 1999-01-28 |
PL183040B1 (pl) | 2002-05-31 |
UA64692C2 (en) | 2004-03-15 |
IL115099A0 (en) | 1995-12-08 |
TW450811B (en) | 2001-08-21 |
NZ296389A (en) | 1999-06-29 |
CN1160344A (zh) | 1997-09-24 |
NO323582B1 (no) | 2007-06-11 |
RU2169555C2 (ru) | 2001-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1138543C (zh) | 水不溶性喜树碱的类脂配合物的冷冻干燥制剂 | |
CN1191067C (zh) | 高不溶性铂配合物的脂质复合物和脂质体 | |
CN101926757B (zh) | 一种难溶性药物的液体组合物及其制备方法 | |
EP1030686B1 (en) | Lyophilizate of lipid complex of water insoluble porphyrins | |
US20090246268A1 (en) | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors | |
CN1927203A (zh) | 聚乙二醇衍生化磷脂包载的长春花生物碱类抗肿瘤药物的纳米胶束制剂 | |
WO2018148432A1 (en) | Sn-38 loaded iron crosslinked micelle and methods thereof | |
US6608050B2 (en) | Lyophilizate of lipid complex of water insoluble porphyrins | |
CN106267227A (zh) | 抗肿瘤药物 | |
WO1995029677A1 (en) | Lactone stable formulation of camptothecin or 7-ethyl camptothecin | |
EP1227795B1 (en) | Lipid complex of alkycyclines | |
CN1875946A (zh) | 10-羟基喜树碱纳米粒及其制备方法 | |
WO2007014150A2 (en) | Method of administering liposomes containing oligonucleotides | |
JP2003509356A (ja) | リン酸エストラムスチン塩およびスルホアルキルエーテルシクロデキストリンの非経口的使用のための処方 | |
CN1903201A (zh) | 10-羟基-9-烯丙基喜树碱的注射制剂及它的制备方法 | |
US20020051778A1 (en) | Method for treatment of malignant neoplasms and a complex preparation having antimalignant activity | |
CN103520159A (zh) | 奎宁类药物和长春新碱类药物共载脂质体及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: American California Applicant after: IDEC Pharmaceutical Corp. Address before: American Ohio Applicant before: Pharmacia, Inc. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: PHARMACIA, INC. TO: IDEC PHARMACEUTICAL CORP. |
|
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
CI01 | Publication of corrected invention patent application |
Correction item: Service bar Correct: delete False: deemed to have been withdrawn Number: 52 Page: 162 Volume: 16 |
|
ERR | Gazette correction |
Free format text: CORRECT: AFFAIR COLUMN; FROM: DEEMED WITHDRAWAL TO: DELETION |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |